| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_239154d7677336c2732909523c5f0f4b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55594
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-015 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-015 |
| filingDate |
2011-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_410d023786edba9cd4bf3091ba756961
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_870e43b4f0fcb90fe5434cb82fb3289a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99e9f0b6297c4b04c362a2bd8f925f4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0fd1b1737395f3c55e85353da945d55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a44d28f55c7b1d3e011a522def65d5c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b31eb58a7bc3185c80fd005636945732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a0721041add93186ac2b40fe2ec4fa0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f0958a5975256848a9744fb75ed21a0 |
| publicationDate |
2013-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2548572-A2 |
| titleOfInvention |
Adjuvanted tolerogens as a malaria vaccine |
| abstract |
The invention relates to the field of vaccinal compositions for the effective or preventive treatment of vertically transmitted infections, especially malaria and preferably human malaria caused by Plasmodium falciparum. The technical aim of the invention is to use the tolerogens transferred, at an early stage, from the mother to the foetus/newborn and to formulate them with potent adjuvants that are inducers of Th1 and cytotoxic T-cell responses in order to use same in prophylactic or therapeutic vaccines against vertically transmitted infections, especially malaria. The use of said formulations at early ages via the parenteral route or via the mucosal route or both at the same time reverts the tolerance induced by the transfer of tolerogens, thereby inducing protective responses. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112956668-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018235058-A1 |
| priorityDate |
2010-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |